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Diabetics are known to develop wounds that are associated
with significant levels of morbidity and mortality. The ma-
jority of amputations in the US are on the diabetic lower
extremity where previous ulceration may have contributed
to infection and additional complications necessitating the
subsequent amputation (National Diabetes Data Group,
1995; Frykberg and Armstrong, 2002).
There is still a need for products that will promote rapid
closure of diabetic wounds, thereby reducing the risk of
infection, wound deterioration, and amputation. However,
the design, development and application of such products
are hindered by the absence of wound models which ad-
equately reproduce the diabetic wound environment, asso-
ciated medical conditions, and extrinsic factors contributing
to delayed wound closure. While the db/db mouse model
recreates a biochemical environment similar to the diabetic
patient, neuropathy, organ failure, medications, concomi-
tant medical problems, and extrinsic factors including off-
loading (pressure reduction and relief at the wound site),
repetitive trauma, and the introduction of environmental
pathogens are currently not possible to reproduce in the
animal model.
Electrical stimulation is known to have a direct effect on
cellular activity, particularly when considering every cell has
an electrical charge, and may be beneficial to wound clo-
sure. Studies demonstrating the positive effects on chronic
wounds, particularly pressure ulcers, are available in the
medical literature (Kloth, 1995). Electrical stimulation is also
used to promote bone repair in cases of non-union occur-
ring post fracture. Electroporation has also been estab-
lished as a method of gene delivery. The concept of
combining electrical therapy with gene therapy may present
yet another useful adjunct in promoting wound closure in
wounds difficult to heal.
Gene therapy, while extensively explored in various med-
ical applications, has only recently been considered as a
treatment for diabetic wounds. Limited Phase 1 trials are
being conducted with a topical gene therapy, a growth fac-
tor sequence delivered in a collagen vehicle and applied to
selected diabetic foot ulcers, to determine the safety and
efficacy of this treatment modality.1 Results of these early
trials are still pending. Application of topically applied
growth factors manufactured using recombinant means,
has demonstrated a statistically significant benefit in the
treatment of diabetic plantar neuropathic foot ulcers with
adequate blood flow (Smiell et al, 1999), but has had limited
clinical success due to cost, clinician acceptance, and dif-
ficulty in addressing the numerous factors contributing to
diabetic ulcer formation.
Combining gene therapy with electrical stimulation may
bring the clinician closer to rapid and successful wound
closure when administered along with appropriate wound
care. The animal model for the latter therapy serves, at best,
as an indicator for treatment potential, yet fails to provide
credible and substantial evidence that the same therapy will
produce comparable results in the diabetic patient. While it
is encouraging to see animal data that suggest possible
benefits, the extrapolation of data, results, and any conclu-
sions from the animal model to the clinical setting are not
possible based on currently available models. Only the im-
plementation of well-designed, prospective, randomized,
controlled, and ideally double-blinded clinical trials will pro-
vide the answer as to whether the novel treatment sug-
gested in the animal trial will eventually flourish and succeed
as a much-needed treatment modality for individuals with
diabetic wounds.
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